Pharmacokinetics in Pediatric Patients: Drug Distribution

Neonates and infants have higher total body water content, approximately 75-90% of body weight versus 60% in adults. This increased water distribution dilutes hydrophilic drugs, resulting in lower plasma concentrations when dosed on a weight basis. Additionally, their elevated extracellular fluid volume (45% versus 25-26% in adults) further contributes to altered drug distribution patterns in early life.

Total body fat in neonates starts low at approximately 12%, peaks at about 30% within the first year, then gradually decreases to the adult value of 18%. This fluctuation influences lipophilic drug distribution, though age-dependent variability is less pronounced compared to hydrophilic drugs. The changing fat composition requires careful consideration when dosing lipophilic medications across different pediatric age groups.

Neonates and infants have reduced concentrations of plasma proteins such as albumin and alpha-acid glycoprotein. Lower protein levels increase the unbound fraction of highly protein-bound drugs in plasma, enhancing their pharmacological activity. For example, phenytoin exhibits a higher unbound fraction in younger patients, increasing its efficacy and requiring adjusted dosing strategies to prevent toxicity.

In neonates, bilirubin competes with drugs for albumin-binding sites, displacing drugs and increasing unbound drug fractions. This competition complicates drug distribution and necessitates careful dosing consideration. The displacement effect is particularly significant in the neonatal period when bilirubin levels are elevated, potentially increasing drug activity and adverse effects.

Pediatric dosing requires consideration of developmental changes in body composition, plasma protein concentrations, total body water, extracellular fluid volume, and total body fat. These factors collectively influence drug distribution and necessitate tailored regimens to achieve therapeutic drug levels while minimizing adverse effects. Understanding these pharmacokinetic principles is essential for safe and effective drug therapy in pediatric patients.

Standard adult dosing on a weight basis may not achieve desired therapeutic effects in children due to their unique physiological differences. Neonates and infants have significantly higher total body water and extracellular fluid volumes, which alter drug distribution patterns. These developmental differences require age-specific dosing strategies to ensure both efficacy and safety in the pediatric population.

Body composition undergoes significant changes during early childhood. Total body water decreases from 75-90% to adult levels of 60%, extracellular fluid normalizes from 45% to 25-26% by age one, and body fat peaks at 30% within the first year before declining to 18%. These compositional shifts progressively alter how both hydrophilic and lipophilic drugs distribute, necessitating dose adjustments as children mature.